Unknown

Dataset Information

0

A single epitope of Epstein-Barr Virus stimulate IgG production in mice.


ABSTRACT: Background:Epstein-Barr virus (EBV) is closely associated with the high incidence of nasopharyngeal carcinoma in worldwide. Vaccination is one strategy with the potential to prevent the occurrence of EBV-associated cancers, but a suitable vaccine is yet to be licensed. Much vaccine development research focuses on the GP350/220 protein of EBV as it contains an immunogenic epitope at residues 147-165, which efficiently stimulates IgG production in vitro. We examined the ability of this epitope (EBVepitope) to induce IgG production in mice. Methods:The antibody binding pattern of the epitope was analyzed using bioinformatics tools. The IgG production in mice were examined by FACS Calibur™ Flow cytometer. Results:The epitope bound the 72A1 monoclonal antibody at the same site as GP350/220 protein, indicating that the epitope should stimulate B cells to produce antibody. Moreover, in vivo administration of EBVepitope successfully induced IgG expression from B cells, compared with controls. Further investigation indicated that the relative number of B cells expressing IgE in EBVepitope-treated mice was lower than controls. Conclusions:Our data suggest that this EBV GP350 epitope is able to induce IgG expression in vivo without causing allergic reactions, and represents a potential EBV vaccine candidate.

SUBMITTER: Widodo 

PROVIDER: S-EPMC6170204 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A single epitope of Epstein-Barr Virus stimulate IgG production in mice.

Widodo   Pristiwanto Bambang B   Rifa'i Muhaimin M   Mustafa Irfan I   Huyop Fahrul Zaman FZ  

Annals of medicine and surgery (2012) 20180919


<h4>Background</h4>Epstein-Barr virus (EBV) is closely associated with the high incidence of nasopharyngeal carcinoma in worldwide. Vaccination is one strategy with the potential to prevent the occurrence of EBV-associated cancers, but a suitable vaccine is yet to be licensed. Much vaccine development research focuses on the GP350/220 protein of EBV as it contains an immunogenic epitope at residues 147-165, which efficiently stimulates IgG production <i>in vitro</i>. We examined the ability of t  ...[more]

Similar Datasets

| S-EPMC8139657 | biostudies-literature
| PRJNA794826 | ENA
| S-EPMC8724419 | biostudies-literature
| S-EPMC5651165 | biostudies-literature
| S-EPMC3197576 | biostudies-literature
| S-EPMC4457436 | biostudies-literature
| S-EPMC9215254 | biostudies-literature
| S-EPMC4822607 | biostudies-literature
| S-EPMC5597738 | biostudies-literature
| S-EPMC6095625 | biostudies-literature